Central Nervous System News and Research

RSS

SCCA, ProCure to open new proton therapy center for cancer treatment

Seattle Cancer Care Alliance, together with ProCure Treatment Centers Inc., today held its ceremonial groundbreaking on a new proton therapy center in north Seattle that will provide a first-of-its-kind treatment option for cancer patients throughout the Northwest.

23 Mar 2011

Insight into 'contagious itch'

Can you catch an itch? The answer is yes. Dermatologist Gil Yosipovitch, M.D., of Wake Forest Baptist Medical Center, has been researching what's known as "contagious itch."

23 Mar 2011

Iron deficiency during pregnancy may impact child's brain development

A mother's iron deficiency early in pregnancy may have a profound and long-lasting effect on the brain development of the child, even if the lack of iron is not enough to cause severe anemia, according to a University of Rochester Medical Center study published in the scientific journal PLoS One.

23 Mar 2011

Study: Stem cell transplant may benefit patients with rapidly progressive MS

A long term study reports about the effectiveness of replacing bone marrow, purposely destroyed by chemotherapy, with autologous stem cell rescue for people with aggressive forms of multiple sclerosis.

22 Mar 2011

Study identifies gene linked to higher risk of multiple sclerosis in children

Canadians have one of the highest rates of Multiple Sclerosis (MS) in the world with approximately 1,000 new cases diagnosed each year. Primarily striking in adulthood, physicians and researchers with the Canadian Pediatric Demyelinating Diseases Network (CPDDN), a multi-institutional and multidisciplinary group, have found that MS is being increasingly diagnosed in children.

21 Mar 2011

Prenatal alcohol exposure another risk for conduct disorder

Alcohol use during pregnancy is common and is associated with significant threats to the health and development of exposed offspring. Despite warnings from the Surgeon General to limit alcohol use if pregnant or contemplating pregnancy, a recent survey by the National Birth Defects Prevention Study(1) found that nearly one-third of women drank alcohol at some time during their pregnancy, with one-fourth of the women surveyed having drunk during the first trimester.

21 Mar 2011

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Nektar Therapeutics today announced that the first subjects were dosed in a new Phase 1 clinical study to evaluate NKTR-181, the company's next-generation opioid analgesic candidate. NKTR-181 is being developed to effectively treat pain while addressing the abuse liability and serious CNS side effects associated with currently available opioid therapies.

21 Mar 2011

Transcranial LED-based light therapy improves cognitive function in traumatic brain injury patients

At-home, daily application of light therapy via light-emitting diodes (LEDs) placed on the forehead and scalp led to improvements in cognitive function and post-traumatic stress disorder in patients with a traumatic brain injury (TBI), according to a groundbreaking study published in Photomedicine and Laser Surgery, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Mar 2011

Vitamin A may play key role in sperm cell formation and development of central nervous system

In a recently-published study mapping the structure and function of the so-called "orphan" nuclear receptor TR4, Van Andel Research Institute (VARI) investigators suggest that Vitamin A may play a more direct role than was previously known in certain physiological functions including sperm cell formation and the development of the central nervous system.

18 Mar 2011

NextGen Sciences introduces multiplex protein assay for oncology biomarker discovery

NextGen Group plc is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first multiple protein assay, plasmadiscovery41, for oncology biomarker discovery and qualification.

16 Mar 2011

Decades-old FDA approved hypertension drug may delay onset and reduce severity of MS

People suffering from multiple sclerosis may benefit if patent-pending research conducted at Purdue University shows that a decades-old drug approved by the FDA to treat hypertension also delays the onset and reduces the severity of MS symptoms.

16 Mar 2011

Gadavist approved by FDA for use in central nervous system MRI scans

The U.S. Food and Drug Administration approved Gadavist (gadobutrol), a gadolinium-based contrast agent, for use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system.

16 Mar 2011

Omeros fourth quarter net loss increases to $7.2 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

15 Mar 2011

New findings help explain why toxoplasmosis causes serious disease

Providing clues into why the severity of a common parasitic infection can vary greatly from person to person, a new Johns Hopkins study shows that each one of three strains of the cat-borne parasite Toxoplasma gondii sets off a unique reaction in the nerve cells it invades.

15 Mar 2011

Bayer receives FDA approval for Gadavist Injection

Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist Injection, a macrocyclic gadolinium-based contrast agent, for intravenous use in diagnostic magnetic resonance imaging in adults and children to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.

14 Mar 2011

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own critical tissues.

11 Mar 2011

Neurogenesis plays a beneficial role in exercise-induced response to stress, sexual behavior and reproduction

Two studies published by an interdisciplinary team of Hong Kong researchers in the current special issue of Cell Transplantation (20:1), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , link the regrowth of key adult brain cells (neurogenesis) in two critical areas of the brain to both the benefits of exercise as a stress reducer and also to sexual behavior and reproductive issues.

11 Mar 2011

Central Nervous System News and Research

SCCA, ProCure to open new proton therapy center for cancer treatment

Insight into 'contagious itch'

Iron deficiency during pregnancy may impact child's brain development

Study: Stem cell transplant may benefit patients with rapidly progressive MS

Study identifies gene linked to higher risk of multiple sclerosis in children

Prenatal alcohol exposure another risk for conduct disorder

Nektar initiates dosing in NKTR-181 Phase 1 clinical study for treatment of pain

Transcranial LED-based light therapy improves cognitive function in traumatic brain injury patients

Vitamin A may play key role in sperm cell formation and development of central nervous system

NextGen Sciences introduces multiplex protein assay for oncology biomarker discovery

Decades-old FDA approved hypertension drug may delay onset and reduce severity of MS

Gadavist approved by FDA for use in central nervous system MRI scans

Omeros fourth quarter net loss increases to $7.2 million

New findings help explain why toxoplasmosis causes serious disease

Bayer receives FDA approval for Gadavist Injection

Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta

Neurogenesis plays a beneficial role in exercise-induced response to stress, sexual behavior and reproduction

SAMHSA study finds 51.5% drug-related hospital visits by older patients

Novartis new MS treatment receives Notice of Compliance in Canada

International panel revises, simplifies 'McDonald Criteria' for diagnosis of multiple sclerosis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News